Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
PHP Toggle Menu

Category: 2024

Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatment

BT-001 ESMO

Published 14 September 2024
Categorized as 2024, BT-001, categorie-orpheline, dates, dates, Press release

TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvionment

L.Fend, et al. ESMO 2024  Abstract available on the CICON website – Download the abstract and the poster

Published 10 September 2024
Categorized as 2024, Invir.IO, Publication, TG6050-en

Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation

Nominations

Published 10 September 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release

Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024

ESMO ABSTRACT

Published 9 September 2024
Categorized as 2024, BT-001, dates, Press release

Transgene to Participate in HTID Conference and Investor Access Forum in Paris

investor events

Published 5 September 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release

TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment

F. Azar et al. Journal for ImmunoTherapy of Cancer July 2024 Article available on JITC website

Published 27 August 2024
Categorized as 2024, Publication, TG6050-en

Transgene — Preclinical Proof of Concept Data of Oncolytic Virus TG6050 published in JITC

TG6050

Published 27 August 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release, TG6050-en

Transgene strengthens its balance sheet via equity conversion of current account advance from TSGH

current account advance

Published 30 July 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release

Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024

BT-001 ESMO 2024

Published 22 July 2024
Categorized as 2024, BT-001, categorie-orpheline, dates, dates, Press release

Transgene – First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer

TG4050

Published 3 June 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release, TG4050

Posts pagination

Newer posts Page 1 Page 2 … Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
Menu